康为世纪 (688426)
Jiangsu Cowin Biotech Co., Ltd.
K-Line Chart
No K-line data available
Company NameJiangsu Kangwei Century Biotechnology Co., Ltd.
Listing Date2022-10-25
Issue Price48.98RMB
Registered Capital11249.371610k RMB
Legal RepresentativeWang Chunxiang
Registered AddressNo. 18 Zelan Road, Medical High-Tech Zone, Taizhou City, Jiangsu Province
IndustryMedical Devices
Main BusinessIndependent R&D of core underlying technologies for molecular detection
Company ProfileKangwei Century Biotechnology Co., Ltd. is a national high-tech enterprise with independent intellectual property rights in the life sciences field. It is primarily engaged in the research, development, and production of high-value-added, high-tech-content biological reagents, providing innovative biological products and services for global life science research, genetic testing, and in vitro diagnostic users. The company has been recognized as a National High-Tech Enterprise, a Jiangsu Provincial Technology-Based SME, a Jiangsu Provincial Gazelle Enterprise, and a Jiangsu Provincial Private Technology Enterprise. To date, the company has invested billions of RMB cumulatively, establishing a specialized, intensive technological innovation system capable of generating independent intellectual property rights and an open cooperative innovation platform, thereby forming a complete R&D and innovation system.
The product line mainly includes molecular diagnostic raw material enzymes, nucleic acid collection and preservation reagents, nucleic acid extraction kits, and molecular diagnostic detection reagents, breaking China's dependence on imported reagents in biological research and industry.
Stock Details
1. Key Indicators
- Total Shares(W): 11249.37
- Circulating A-Shares(W): 3799.33
- Earnings Per Share(RMB): -0.6900
- Net Assets Per Share(RMB): 12.3609
- Operating Revenue(W RMB): 13957.42
- Total Profit(W RMB): -8188.00
- **Net Profit Attributable to Parent(W RMB) **: -7616.26
- Net Profit Growth Rate(%): 20.37
- Weighted Return on Equity(%): -5.3500
- Operating Cash Flow Per Share(RMB): -0.6390
- Undistributed Profit Per Share(RMB): -0.8231
- Capital Reserve Per Share(RMB): 12.4332
2. Main Business
The main business covers:
- Independent R&D of core underlying technologies for molecular detection
3. Company Basic Information
- Company Name: Jiangsu Kangwei Century Biotechnology Co., Ltd.
- Listing Date: 2022-10-25
- Industry: Pharmaceutical Manufacturing
- Address: 4th Floor, TQB Building, No.1 Yaocheng Avenue, Taizhou City, Jiangsu Province
- Website: https://www.cwbio.com/
- Company Profile: The company was established in 2020 through the overall transformation of Jiangsu Kangwei Century Biotechnology Co., Ltd., focusing on the independent R&D of core underlying technologies for molecular detection. It was listed on the Shanghai Stock Exchange STAR Market on October 25, 2022.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Rongtong Health Industry Flexible Allocation Hybrid Securities Investment Fund Class A | Fund | 260.00 | 6.84 |
| 2 | Jiangsu Kangwei Century Biotechnology Co., Ltd. Special Securities Account for Repurchase | General Legal Person | 256.19 | 6.74 |
| 3 | CITIC Securities - China CITIC Bank - CITIC Securities Kangwei Century Employee Participation in STAR Market Strategic Placement Collective Asset Management Plan | General Legal Person | 105.19 | 2.77 |
| 4 | Yuanxinyongfeng Medicine and Health Hybrid Securities Investment Fund Class A | Fund | 95.00 | 2.50 |
| 5 | Honghui Holding Group Co., Ltd. | General Legal Person | 91.00 | 2.40 |
| 6 | Anhui Jingxi Private Fund Management Co., Ltd. - Jingxi Yangfan Qiming No.2 Private Securities Investment Fund | Private Securities Investment Fund | 82.00 | 2.16 |
| 7 | Shenzhen Hanjinliang Private Fund Management Co., Ltd. - Hanjinliang Allocation No.6 Private Securities Investment Fund | Private Securities Investment Fund | 80.27 | 2.11 |
| 8 | Jiangsu Yida Achievements Innovation and Entrepreneurship Investment Fund (Limited Partnership) | General Legal Person | 73.00 | 1.92 |
| 9 | Taizhou City Transformation and Upgrade Industrial Investment Fund (Limited Partnership) | General Legal Person | 73.00 | 1.92 |
| 10 | Rongtong Value Growth Hybrid Securities Investment Fund Class A | Fund | 45.00 | 1.18 |
5. Concept Sectors
- Gene Concept
- Helicobacter Pylori
- Margin Trading & Securities Lending
- Consecutive Losses
- Below IPO Price
- High Margin Financing
- Fund Reduction
- New Private Placement
- Micro/Small Cap Stock
Remarks
- Data update date: 2025-11-01
- Data source: Public Market Information